Prevalence and Effect on Survival of Pre-treatment Sarcopenia in Patients with Hematological Malignancies: a Meta-analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Oct 23

PMID 37869092

Authors

Jianzhu Xiong

Kangkang Chen

Wen Huang

Mingang Huang

Feiyan Cao

Yiwen Wang

Qifeng Chen

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Evidence regarding the prevalence of pre-treatment sarcopenia and its impact on survival in patients with hematological malignancies (HM) varies across studies. We conducted a systematic review and meta-analysis to summarize this discrepancy.

Methods: PubMed, Embase and Cochrane library were systematically searched for relevant studies. Outcomes assessed were: prevalence of pre-treatment sarcopenia, overall survival (OS), progression-free survival (PFS) and complete response (CR). Weighted mean proportion, odds ratios (ORs) and hazard ratios (HRs) were estimated using a fixed-effects and a random-effects model.

Results: A total of 27 retrospective cohort studies involving 4,991 patients were included in this study. The prevalence of pre-treatment sarcopenia was 37.0% (95% CI: 32.0%-42.0%) in HM patients <60 years and 51.0% (95% CI: 45.0%-57.0%) in≥60 years. Patients with leukemia had the lowest prevalence, compared with those with other HM (38.0%; 95% CI: 33.0%-43.0%; = 0.010). The presence of sarcopenia was independently associated with poor OS (HR = 1.57, 95% CI = 1.41-1.75) and PFS (HR = 1.50, 95% CI = 1.22-1.83) throughout treatment period, which may be partially attributed to decreased CR (OR = 0.54, 95% CI = 0.41-0.72), particularly for BMI ≥ 25 ( = 0.020) and males ( = 0.020).

Conclusion: Sarcopenia is highly prevalent in patients with HM and an adverse prognostic factor for both survival and treatment efficacy. HM and sarcopenia can aggravate each other. We suggest that in future clinical work, incorporating sarcopenia into risk scores will contribute to guide patient stratification and therapeutic strategy, particularly for the elderly.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier (CRD42023392550).

Citing Articles

Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Zhang S, Tang Z Front Immunol. 2024; 15:1291840.

PMID: 38469315 PMC: 10925676. DOI: 10.3389/fimmu.2024.1291840.

References

Albano D, Dondi F, Treglia G, Tucci A, Ravanelli M, Farina D . Longitudinal Body Composition Changes Detected by [F]FDG PET/CT during and after Chemotherapy and Their Prognostic Role in Elderly Hodgkin Lymphoma. Cancers (Basel). 2022; 14(20). PMC: 9601090. DOI: 10.3390/cancers14205147. View

Beaudart C, Biver E, Reginster J, Rizzoli R, Rolland Y, Bautmans I . Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle. 2016; 8(2):238-244. PMC: 5377391. DOI: 10.1002/jcsm.12149. View

Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin M, McCargar L . Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31(12):1539-47. DOI: 10.1200/JCO.2012.45.2722. View

Lin R, Michaud L, Lobaugh S, Nakajima R, Mauguen A, Elko T . The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. Leuk Lymphoma. 2020; 61(8):1833-1841. PMC: 7429343. DOI: 10.1080/10428194.2020.1742909. View

Meyer H, Wienke A, Surov A . Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis. Nutr Cancer. 2022; 74(10):3518-3526. DOI: 10.1080/01635581.2022.2077387. View

Surov A, Wienke A . Sarcopenia predicts overall survival in patients with malignant hematological diseases: A meta-analysis. Clin Nutr. 2020; 40(3):1155-1160. DOI: 10.1016/j.clnu.2020.07.023. View

Ando T, Fujisawa S, Teshigawara H, Matsumura A, Sakuma T, Suzuki T . Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. Int J Hematol. 2020; 112(1):46-56. DOI: 10.1007/s12185-020-02870-5. View

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

Liu H, Chen J, Shao W, Yan S, Ding S . Efficacy and safety of Omega-3 polyunsaturated fatty acids in adjuvant treatments for colorectal cancer: A meta-analysis of randomized controlled trials. Front Pharmacol. 2023; 14:1004465. PMC: 10151497. DOI: 10.3389/fphar.2023.1004465. View

10.

Jullien M, Tessoulin B, Ghesquieres H, Oberic L, Morschhauser F, Tilly H . Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. Cancers (Basel). 2021; 13(18). PMC: 8466314. DOI: 10.3390/cancers13184503. View

11.

Malmstrom T, Miller D, Simonsick E, Ferrucci L, Morley J . SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016; 7(1):28-36. PMC: 4799853. DOI: 10.1002/jcsm.12048. View

12.

Go S, Kim H, Kang M, Park S, Lee G . Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma. BMC Cancer. 2020; 20(1):439. PMC: 7236094. DOI: 10.1186/s12885-020-06921-2. View

13.

Bone A, Hepgul N, Kon S, Maddocks M . Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis. 2016; 14(1):85-99. PMC: 5720213. DOI: 10.1177/1479972316679664. View

14.

Yang M, Shen Y, Tan L, Li W . Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis. Chest. 2019; 156(1):101-111. DOI: 10.1016/j.chest.2019.04.115. View

15.

Takenaka Y, Oya R, Takemoto N, Inohara H . Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. J Cachexia Sarcopenia Muscle. 2021; 12(5):1122-1135. PMC: 8517360. DOI: 10.1002/jcsm.12755. View

16.

Go S, Park M, Song H, Kim H, Kang M, Lee H . Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle. 2016; 7(5):567-576. PMC: 4833756. DOI: 10.1002/jcsm.12115. View

17.

Xu X, He D, Tian M, Wu H, Jin X . Prognostic Value of Sarcopenia in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Systematic Review and Meta-Analysis. Front Nutr. 2022; 9:816883. PMC: 8914205. DOI: 10.3389/fnut.2022.816883. View

18.

Hojman P, Gehl J, Christensen J, Pedersen B . Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. Cell Metab. 2017; 27(1):10-21. DOI: 10.1016/j.cmet.2017.09.015. View

19.

Rier H, Kharagjitsing H, van Rosmalen J, van Vugt J, Westerweel P, de Jongh E . Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2020; 61(7):1618-1626. DOI: 10.1080/10428194.2020.1737686. View

20.

Ferraro V, Thormann M, Hinnerichs M, Pech M, Wolleschak D, Mougiakakos D . Sarcopenia does not predict outcome in patients with CNS lymphoma undergoing systemic therapy. Oncol Lett. 2022; 24(4):355. PMC: 9478615. DOI: 10.3892/ol.2022.13475. View